Perrigo Company Intrinsic Value – PERRIGO COMPANY Reports Third Quarter FY2023 Earnings Results as of September 30 2023

🌥️Earnings Overview

On November 7, PERRIGO COMPANY ($NYSE:PRGO) reported its earnings results for the third quarter of FY2023, ending September 30 2023. Total revenue for the period was USD 1123.8 million, a 2.1% improvement from the same quarter in the prior year. Net income showed a 128.7% increase from the same period last year, amounting to USD 14.2 million.

Share Price

The stock opened at $26.9 and closed at $29.6, marking a 4.0% increase from the previous closing price of 28.5. This marks PERRIGO COMPANY‘s sixth consecutive quarter of year over year earnings growth. The company is now well positioned for further growth moving forward, with an expected increase in revenue and earnings in the next quarter. PERRIGO COMPANY has been able to weather the economic impact of the pandemic through cost-cutting initiatives and diversifying its business practices. The company has also been able to capitalize on emerging trends in the healthcare and consumer products industries, making strategic investments to increase its market share.

This has allowed PERRIGO COMPANY to remain profitable and increase its dividends to shareholders. The company’s third quarter results show that it is continuing to benefit from the cost-cutting initiatives and increased focus on consumer product sales. Overall, PERRIGO COMPANY has continued to show strong earnings results, as evidenced by its Q3 performance. The company is well positioned to continue its growth trajectory in the coming quarters, with investors looking forward to continued increases in revenue and earnings. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Perrigo Company. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Perrigo Company. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Perrigo Company. More…

Key Ratios Snapshot

Some of the financial key ratios for Perrigo Company are shown below. More…

Analysis – Perrigo Company Intrinsic Value

At GoodWhale, we have conducted an analysis of PERRIGO COMPANY‘s wellbeing. Our proprietary Valuation Line calculated the fair value of PERRIGO COMPANY share to be around $38.9. However, currently the stock is trading at $29.6, resulting in a 23.9% undervaluation. This presents a unique opportunity for investors to capitalize on the potential upside of the stock. More…

Peers

Yuhan Corp, JW Pharmaceutical and Lavipharm SA are all competitors of Perrigo Co PLC.

– Yuhan Corp ($KOSE:000105)

Yuhan Corp is a South Korean conglomerate that operates in the pharmaceutical and chemical industries. It has a market cap of 3.83T as of 2022 and a Return on Equity of 4.29%. The company was founded in 1926 and is headquartered in Seoul. It is one of the largest companies in South Korea and is a major player in the global pharmaceutical market.

– JW Pharmaceutical ($KOSE:001060)

As of 2022, JW Pharmaceutical has a market cap of 396.36B and a Return on Equity of 13.04%. The company is a global pharmaceutical company that develops, manufactures, and markets prescription and over-the-counter medicines.

Summary

PERRIGO COMPANY‘s third quarter of FY2023 financial results revealed total revenue of USD 1123.8 million, a 2.1% increase from the same period in the prior year. Net income rose by 128.7% year-over-year to USD 14.2 million. Following the release of these results, the stock price moved up on the same day. This positive reaction to the financials indicates that PERRIGO COMPANY is a solid investment option for investors. With strong revenue growth and increasing profits, the company is well-positioned to deliver future returns.

However, it is important to carefully consider the risks associated with such an investment before committing capital.